Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,010.10 | 117.10 | -1.28% |
CAC 40 | 7,654.25 | 53.65 | -0.70% |
DAX 40 | 23,487.33 | 550.00 | -2.29% |
Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
FTSE 100 | 9,116.69 | 79.65 | -0.87% |
HKSE | 25,304.47 | 192.08 | -0.75% |
NASDAQ | 21,279.63 | 175.92 | -0.82% |
Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
S&P 500 | 6,415.54 | 44.72 | -0.69% |
S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
SSE Composite Index | 3,802.77 | 55.36 | -1.43% |